VEGF bispecifics make inroads in other cancers, and more: Clinical Report

VEGF bispecifics gained the spotlight when Akeso reported that ivonescimab beat Keytruda in a head-to-head non-small cell lung cancer study last year, and now they are proving their potential beyond lung cancer.

On Tuesday, Compass Therapeutics Inc. (NASDAQ:CMPX) reported that tovecimig, a DLL4 x VEGF-A bispecific antibody, led to a 17.1% overall response rate when combined with paclitaxel as second-line therapy for biliary tract cancer. The control arm — paclitaxel alone — led to a 5.3% ORR (p=0.031)...